PubRank

S A Santoro

Author PubWeight™ 92.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990 3.35
2 The membrane glycoprotein Ia-IIa (VLA-2) complex mediates the Mg++-dependent adhesion of platelets to collagen. J Cell Biol 1989 2.44
3 Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J Cell Sci 1995 2.39
4 Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell 1986 2.38
5 Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. J Mammary Gland Biol Neoplasia 1998 2.30
6 A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc Natl Acad Sci U S A 1985 2.04
7 Isolation and characterization of a heparin-binding domain from the amino terminus of platelet thrombospondin. J Biol Chem 1984 1.94
8 The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids. J Biol Chem 1985 1.90
9 Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. Blood 1985 1.87
10 Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 1990 1.82
11 The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995 1.80
12 Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci U S A 1995 1.80
13 Identification of a tetrapeptide recognition sequence for the alpha 2 beta 1 integrin in collagen. J Biol Chem 1991 1.79
14 Mapping of epitopes for monoclonal antibodies against human platelet thrombospondin with electron microscopy and high sensitivity amino acid sequencing. J Cell Biol 1985 1.62
15 Widespread histologic distribution of the alpha 2 beta 1 integrin cell-surface collagen receptor. Am J Pathol 1990 1.48
16 Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. J Biol Chem 2001 1.46
17 Decorin binds near the C terminus of type I collagen. J Biol Chem 2000 1.40
18 The spatial and temporal expression of the alpha 2 beta 1 integrin and its ligands, collagen I, collagen IV, and laminin, suggest important roles in mouse mammary morphogenesis. Differentiation 1995 1.38
19 Localization of the hemagglutinating activity of platelet thrombospondin to a 140 000-dalton thermolytic fragment. Biochemistry 1984 1.33
20 Competition for related but nonidentical binding sites on the glycoprotein IIb-IIIa complex by peptides derived from platelet adhesive proteins. Cell 1987 1.30
21 Activated platelets express IL-1 activity. J Immunol 1989 1.24
22 alpha 2 integrin subunit cytoplasmic domain-dependent cellular migration requires p38 MAPK. J Biol Chem 2000 1.22
23 Effects of anti-thrombospondin monoclonal antibodies on the agglutination of erythrocytes and fixed, activated platelets by purified thrombospondin. Biochemistry 1985 1.21
24 Isolation of the fibrinogen-binding region of platelet thrombospondin. Biochem Biophys Res Commun 1984 1.17
25 Collagen receptor control of epithelial morphogenesis and cell cycle progression. Am J Pathol 1999 1.16
26 The alpha 2 beta 1 integrin cell surface collagen receptor binds to the alpha 1 (I)-CB3 peptide of collagen. J Biol Chem 1990 1.16
27 Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994 1.16
28 Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol 1993 1.15
29 Ligand recognition by the I domain-containing integrins. Cell Mol Life Sci 1998 1.14
30 Induced cell surface expression of functional alpha 2 beta 1 integrin during megakaryocytic differentiation of K562 leukemic cells. Exp Cell Res 1992 1.14
31 Loss of MDCK cell alpha 2 beta 1 integrin expression results in reduced cyst formation, failure of hepatocyte growth factor/scatter factor-induced branching morphogenesis, and increased apoptosis. J Cell Sci 1995 1.10
32 A three-dimensional collagen lattice activates NF-kappaB in human fibroblasts: role in integrin alpha2 gene expression and tissue remodeling. J Cell Biol 1998 1.09
33 ERK and p38 MAP kinase pathways are mediators of intestinal epithelial wound-induced signal transduction. Biochem Biophys Res Commun 1997 1.09
34 Inhibition of platelet aggregation by a monoclonal antibody against human fibronectin. Proc Natl Acad Sci U S A 1985 1.06
35 Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994 1.06
36 Complex patterns of expression suggest extensive roles for the alpha 2 beta 1 integrin in murine development. Dev Dyn 1994 1.02
37 The human alpha 2 integrin gene promoter. Identification of positive and negative regulatory elements important for cell-type and developmentally restricted gene expression. J Biol Chem 1994 1.02
38 Adsorption of von Willebrand factor by fibrillar collagen--implications concerning the adhesion of platelets to collagen. Coll Relat Res 1982 1.01
39 Specific residues within the alpha 2 integrin subunit cytoplasmic domain regulate migration and cell cycle progression via distinct MAPK pathways. J Biol Chem 2001 0.99
40 Fibronectin and the multiple interaction model for platelet-collagen adhesion. Proc Natl Acad Sci U S A 1979 0.98
41 Bone matrix constituents stimulate interleukin-1 release from human blood mononuclear cells. J Clin Invest 1991 0.97
42 More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996 0.97
43 Isolation and characterization of thrombospondin. Methods Enzymol 1987 0.96
44 Determinants of ligand binding specificity of the alpha(1)beta(1) and alpha(2)beta(1) integrins. J Biol Chem 1999 0.95
45 Collagen-mediated platelet aggregation. Evidence for multivalent interactions of intermediate specificity between collagen and platelets. J Clin Invest 1977 0.94
46 Downstream events in mammary gland morphogenesis mediated by reexpression of the alpha2beta1 integrin: the role of the alpha6 and beta4 integrin subunits. Cancer Res 1998 0.94
47 Inhibition of platelet aggregation by fibronectin. Biochem Biophys Res Commun 1983 0.93
48 Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res 1981 0.93
49 Collagen-induced release of interleukin 1 from human blood mononuclear cells. Potentiation by fibronectin binding to the alpha 5 beta 1 integrin. J Clin Invest 1992 0.92
50 PDGF induction of alpha 2 integrin gene expression is mediated by protein kinase C-zeta. J Cell Biol 1996 0.91
51 Mammary epithelial cell-cycle progression via the alpha(2)beta(1) integrin: unique and synergistic roles of the alpha(2) cytoplasmic domain. Am J Pathol 2001 0.91
52 Characterization of the platelet agglutinating activity of thrombospondin. Biochemistry 1985 0.90
53 Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction. J Biol Chem 2001 0.90
54 Antiphospholipid antibodies and thrombotic predisposition: underlying pathogenetic mechanisms. Blood 1994 0.90
55 Differential expression of integrin alpha subunits supports distinct roles during lung branching morphogenesis. Dev Dyn 1996 0.89
56 Contributions of the I and EF hand domains to the divalent cation-dependent collagen binding activity of the alpha2beta1 integrin. J Biol Chem 1997 0.89
57 Transcriptional regulation of alpha IIb integrin gene expression during megakaryocytic differentiation of K562 cells. Role of a silencer element. J Biol Chem 1994 0.87
58 Differential regulation of the alpha 2 beta 1 and alpha IIb beta 3 integrin genes during megakaryocytic differentiation of pluripotential K562 cells. J Biol Chem 1992 0.86
59 Collagen-mediated platelet aggregation: the role of multiple interactions between the platelet surface and collagen. Thromb Haemost 1980 0.86
60 The ups and downs of alpha 2 beta 1-integrin expression: contributions to epithelial cell differentiation and the malignant phenotype. Curr Top Microbiol Immunol 1998 0.83
61 Evaluation of complete blood count results from a new, on-site hemocytometer compared with a laboratory-based hemocytometer. Crit Care Med 1996 0.82
62 Integrins and the kidney: biology and pathobiology. Curr Opin Nephrol Hypertens 1999 0.82
63 Immunolocalization of alpha-integrin subunits and extracellular matrix components during human colonic organogenesis. Gastroenterology 1996 0.80
64 Interactions of exercise, coagulation, platelets, and fibrinolysis--a brief review. Med Sci Sports Exerc 1988 0.80
65 Preferential binding of high molecular weight forms of von Willebrand factor to fibrillar collagen. Biochim Biophys Acta 1983 0.80
66 Monitoring activity of fibrinolytic agents. A therapeutic challenge. Am J Med 1984 0.79
67 Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg 1997 0.79
68 Binding of the alpha 2 integrin I domain to extracellular matrix ligands: structural and mechanistic differences between collagen and laminin binding. Cell Adhes Commun 1998 0.78
69 Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 1991 0.78
70 Platelet-collagen adhesion-membrane fluidity and the development of high affinity adhesion through multiple interacting sites. Coll Relat Res 1981 0.77
71 Platelet-collagen adhesion. Methods Enzymol 1982 0.77
72 In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients. Anesth Analg 1994 0.77
73 Echoviruses 1 and 8 are closely related genetically, and bind to similar determinants within the VLA-2 I domain. Virus Res 2001 0.77
74 Thrombin enhanced adhesion of platelets to von Willebrand factor substrates. Thromb Res 1986 0.77
75 Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996 0.77
76 Role of the alpha1 and alpha2 integrin cytoplasmic domains in cell morphology, motility and responsiveness to stimulation by the protein kinase C pathway. Cell Adhes Commun 2000 0.77
77 Differential effects of concanavalin A and succinyl concanavalin A on the macromolecular events of platelet activation. Biochim Biophys Acta 1983 0.77
78 New RGD analogue inhibits human platelet adhesion and aggregation and eliminates platelet deposition on canine vascular grafts. J Vasc Surg 1992 0.76
79 Dependence of plasmin-mediated degradation of platelet adhesive receptors on temperature and Ca2+. Blood 1990 0.76
80 Mechanisms of vascular graft thrombosis: role of altered canine platelet sensitivity to thromboxane. Thromb Res 1989 0.76
81 Extracellular FGF-1 inhibits cytoskeletal organization and promotes fibroblast motility. Growth Factors 2000 0.76
82 On-site prothrombin time, activated partial thromboplastin time, and platelet count. A comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery. Anesthesiology 1994 0.75
83 Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. Thromb Res 1997 0.75
84 Mechanism of inhibition by trinitrophenylation of the ristocetin cofactor activity of von Willebrand factor. Biochim Biophys Acta 1984 0.75
85 Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts. Am J Kidney Dis 1997 0.75
86 Amino group modification inhibits ristocetin cofactor activity of human von Willebrand factor. Biochem Biophys Res Commun 1982 0.75
87 The alpha 2 beta 1 integrin binds to the CB4 peptide of the alpha 2(I) collagen chain. Biochem Mol Biol Int 1997 0.75
88 Preparation of soluble peptide libraries: application to studies of platelet adhesion sequences. Biochem Int 1992 0.75
89 Ligand binding results in divalent cation displacement from the alpha 2 beta 1 integrin I domain: evidence from terbium luminescence spectroscopy. Biochemistry 1998 0.75
90 Divalent cation-dependent structure in the platelet membrane glycoprotein Ia-IIa (VLA-2) complex. Biochem Biophys Res Commun 1990 0.75
91 Alpha2beta1 integrin recognition of the carboxyl-terminal propeptide of type I procollagen: integrin recognition and feed-back regulation of matrix biosynthesis are mediated by distinct sequences. Matrix Biol 1998 0.75
92 Duplicate coagulation assays warranted. Am J Clin Pathol 1985 0.75
93 Multiple episodes of thrombosis with biventricular support devices with inadequate anticoagulation and evidence of accelerated intravascular coagulation. J Thorac Cardiovasc Surg 1997 0.75
94 Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay. Am J Clin Pathol 1988 0.75
95 Platelet interactions with fibronectin: divalent cation-independent platelet adhesion to the gelatin-binding domain of fibronectin. Blood 1993 0.75
96 Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitor. Crit Care Med 1995 0.75
97 The nature of interactions between tissue-type plasminogen activator and platelets. Thromb Res 1990 0.75
98 Platelets: platelet immunobiology. Science 1989 0.75
99 Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. Ann Thorac Surg 1995 0.75
100 Platelet interactions with the vessel wall and prosthetic grafts. Ann Vasc Surg 1993 0.75